Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $26 to $20.
Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $26 to $20.
